ENDRA Life Sciences Inc. (NDRA)

Over the past six months, ENDRA Life Sciences' stock has experienced a decline of 11.59% over the last six months and 15.43% over the last month as of early February 2026. In December 2025, ENDRA announced positive results from its 2025 TAEUS® Liver study. In November 2025, a feasibility study demonstrated TAEUS® accurately quantifies liver fat fraction, and the company recapped major milestones and announced its third-quarter 2025 financial results, with an EPS of $-1.75. The launch of a crypto treasury with a $3 million HYPE token purchase resulted in a negative market reaction. In January 2026, a director reported a stock-based award of restricted stock units. The stock's 52-week range has been between $2.90 and $11.96.

There is an indication of seasonality in the demand for ENDRA Life Sciences' products and services, with a "Seasonality Move" of 5.28%. Equity Clock provides seasonal chart data for NDRA, suggesting that the stock's performance may exhibit seasonal patterns.

ENDRA Life Sciences, Inc., based in Ann Arbor, Michigan, is a medical diagnostics company focused on developing and commercializing its TAEUS® technology, a non-invasive diagnostic platform designed to assess tissue fat content. The company's primary focus is on measuring liver fat to diagnose and monitor steatotic liver disease (SLD), formerly known as NAFLD-NASH. ENDRA is also exploring additional applications for its TAEUS® technology, including temperature monitoring during thermoablative surgery and vascular imaging.

Headquartered in Ann Arbor, Michigan, ENDRA Life Sciences is pursuing regulatory approvals for its TAEUS® technology in the U.S. and the European Union. The company is implementing a multi-market commercialization strategy, targeting pharmaceutical companies, clinical research organizations, concierge medical practices, and bariatric/metabolic clinics.

ENDRA Life Sciences' brand reputation has been influenced by positive clinical developments and a controversial financial decision. Positive attention was received for clinical study results demonstrating TAEUS® Liver technology's performance in quantifying liver fat. However, the launch of a crypto treasury with a $3 million HYPE token purchase led to a negative market reaction, impacting its reputation.

As of early February 2026, ENDRA Life Sciences Inc. has 8 institutional owners and shareholders holding a total of 25,929 shares, representing 1.19% of the stock. Major institutional shareholders include Vanguard Group Inc, DRW Securities, LLC, and others. Insider sentiment is positive, with 10 different insiders buying shares over the last year.